Oasmia successfully completes private placement of approximately SEK 72 million

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) today announces that it has completed a private placement of 3,800,000 new shares, providing the Company with approximately SEK 72 million before transaction related costs.

| Source: Oasmia Pharmaceutical AB

Uppsala, Sweden, 2014-03-07 07:59 CET (GLOBE NEWSWIRE) --  

The private placement, which was announced on March 6, 2014, has allowed Oasmia to place 3,800,000 new shares with international institutional investors and qualified investors in Sweden at a price of SEK 19 per share through an accelerated book building procedure.

The proceeds from the Private Placement are intended to strengthen the working capital as well as finance the continued operations and further development of additional human and veterinary products based on the XR-17 technology.

For the purpose of the private placement, the Board of Directors of Oasmia has resolved, pursuant to the authorization granted by the annual general meeting held on September 30, 2013, on a directed issue of 3,800,000 new shares. The reason for deviating from the shareholders’ preferential rights by conducting a directed new share issue is to broaden the shareholder base.

Through the issue, the number of shares in Oasmia increases by 3,800,000 from 81,772,330 to 85,572,330 and the share capital increases by SEK 380,000 from SEK 8,177,233 to SEK 8,557,233. The new issue results in an equity dilution of approximately 4 percent after completed issue. A large existing shareholder has undertaken to temporarily lend the number of shares required to facilitate prompt delivery of the new shares.

Carnegie Investment Bank is acting as manager and sole bookrunner.

The information above has been made public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published on March 7, 2014 at 08.00 am CET.

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia’s shares, ISIN SE0000722365, are listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX).

Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the constituent information in accordance with the rules and regulations prevailing in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Oasmia Pharmaceutical AB (publ) securities in any jurisdiction, neither from Oasmia Pharmaceutical AB (publ), Carnegie Investment Bank AB (publ) nor anyone else.

         Mikael Widell, Vice President Communications Mobile: +46 70 311 99 60 E-mail: mikael.widell@oasmia.com